MARKET

ROIV

ROIV

Roivant Sciences
NASDAQ
26.52
-0.83
-3.03%
After Hours: 26.52 0 0.00% 16:34 03/27 EDT
OPEN
27.26
PREV CLOSE
27.35
HIGH
27.51
LOW
26.47
VOLUME
3.01M
TURNOVER
--
52 WEEK HIGH
30.33
52 WEEK LOW
8.73
MARKET CAP
18.98B
P/E (TTM)
-22.6977
1D
5D
1M
3M
1Y
5Y
1D
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success
Simply Wall St · 14h ago
Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports
Reuters · 1d ago
ROIVANT SCIENCES LTD - FDA GRANTS PRIORITY REVIEW TO BREPOCITINIB NDA WITH PDUFA DATE IN Q3 2026
Reuters · 1d ago
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Barchart · 1d ago
Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?
Simply Wall St · 2d ago
Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit
Reuters · 6d ago
Weekly Report: what happened at ROIV last week (0316-0320)?
Weekly Report · 6d ago
Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2025 Update
Seeking Alpha · 03/23 00:09
More
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Webull offers Roivant Sciences Ltd stock information, including NASDAQ: ROIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIV stock methods without spending real money on the virtual paper trading platform.